Abstract Library

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4654 Usefulness of soluble tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors R2 and R3 in progression assessment of gastroenteropancreatic neuroendocrine neoplasms – A preliminary study

Introduction: TRAIL is a member of TNF family and appears in membrane and soluble (s) forms. It acts either triggering (R1 and R2) or blocking (R3 and R4) apoptosis. TRAIL targeted therapy is widely studied and known as potentially effective in number of neoplasms.

Conference:

Presenting Author: Kaczmarska-Turek D

Authors: Kaczmarska-Turek D, Radziszewski M, Matałowski M, Liszcz A, Bartoszewicz Z,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, tumour necrosis factor-related apoptosis-inducing ligand, tumour progression, PRRT, TRAIL, GEP-NEN,

#4593 Excellent response to Ac-225 DOTATATE therapy in a patient with small cell lung cancer

Introduction: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for patients with NETs overexpressing somatostatin receptors (SSTR). IHC analysis indicates that up to 50% of small cell lung cancer (SCLC) tumours are SSTR2 positive and thus can be targeted by SSR imaging and PRRT. Therapy with α-emitting radionuclides, such as Ac225, may offer several advantages over β-emitters by having higher energy transfer and more effective cancer cell death.

Conference:

Presenting Author: Tuncel M

Authors: Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S,

Keywords: Ac-225 DOTATATE, Small Cell lung cancer, PET, somatostatin receptor, PRRT,

#4586 Base on neuroendocrine tumour classification in CT imaging using pretrained vision transformers and data augmentation

Introduction: Neuroendocrine tumours (NETs) are a group of cancers that can be difficult to distinguish from other malignancies in CT imaging. Their diverse appearance often leads to diagnostic challenges, requiring advanced techniques to improve classification accuracy. Pretrained Vision Transformers (ViTs) have shown promise in medical image analysis, but additional methods are needed to enhance model robustness, particularly when dealing with complex and heterogeneous tumour characteristics.

Conference:

Presenting Author:

Authors: Li H, Tang Z, Ding Z, Chen Y, Li H,

Keywords: Vision transformers, Cancer Detection, Transfer Learning, Medical Image Analysis,

#4549 Alpha-Fetoprotein as a valuable biomarker in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a rare group of tumours that pose a significant diagnostic, therapeutic, and prognostic challenge. This complexity arises from the diversity and heterogeneity of these neoplasms, as well as from the limitations of commonly used biomarkers in clinical practice. Alpha-fetoprotein (AFP) is a fetal protein widely used primarily for congenital defects in prenatal diagnostics and in certain malignancies in adults.

Conference:

Presenting Author:

Authors: Musiałkiewicz J, Gut P, Komarnicki P, Maciejewski A, Ruchała M,

Keywords: alpha-fetoprotein, biomarker, neuroendocrine tumour,